Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia Eisai Oct 02, 2024 10:28 HKT/SGT Read More
Rozebalamin(R) for Injection 25 mg (Mecobalamin) Approved in Japan for Amyotrophic Lateral Sclerosis Eisai Sep 24, 2024 15:06 HKT/SGT Read More
Anticancer Agent "Tasfygo(R) Tablets 35mg" (Tasurgratinib Succinate) Approved in Japan for Biliary Tract Cancer with FGFR2 Gene Fusions or Rearrangements Eisai Sep 24, 2024 14:01 HKT/SGT Read More
Ainos、治療法が限られている希少疾患であるシェーグレン症候群の治療薬VELDONAの台湾での臨床試験開始計画を発表 Ainos, Inc Sep 19, 2024 21:00 JST Read More
LENVIMA(R) (lenvatinib) Plus KEYTRUDA(R) (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) Eisai Sep 17, 2024 09:08 HKT/SGT Read More
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024 Eisai Sep 05, 2024 15:59 HKT/SGT Read More
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates Eisai Aug 14, 2024 08:59 HKT/SGT Read More
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines NEC Corporation Aug 08, 2024 10:12 HKT/SGT Read More
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation Eisai Aug 06, 2024 12:15 HKT/SGT Read More
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 Eisai Jul 31, 2024 12:59 HKT/SGT Read More
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) Eisai Jul 02, 2024 12:01 HKT/SGT Read More
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City Eisai Jun 21, 2024 14:35 HKT/SGT Read More
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Jun 10, 2024 17:50 HKT/SGT Read More
エーザイとバイオジェン、早期アルツハイマー病治療剤「レケンビ(R)」の静注維持投与に関する生物製剤承認一部変更申請が米国FDAにより受理 Eisai Jun 10, 2024 13:00 JST Read More
Eisai Named to List of The Time 100 Most Influential Companies Eisai Jun 03, 2024 16:08 HKT/SGT Read More
